Fulcrum Therapeutics, Inc.
General ticker "FULC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $579.1M (TTM average)
Fulcrum Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -14.0%.
Estimated limits based on current volatility of 3.4%: low 3.46$, high 3.70$
Factors to consider:
- Total employees count: 51 (-32.9%) as of 2024
- Top business risk factors: Liquidity and credit risks, Clinical trial failure, Regulatory and compliance, Manufacturing risks, IP infringement
- Current price 48.6% below estimated low
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.11$, 17.16$]
- 2026-12-31 to 2027-12-31 estimated range: [5.58$, 13.89$]
Financial Metrics affecting the FULC estimates:
- Positive: with PPE of -10.1 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 4.06 > -0.60
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of 0 <= 0
Short-term FULC quotes
Long-term FULC plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2.81MM | $80.00MM | $0.00MM |
| Operating Expenses | $113.47MM | $101.90MM | $84.77MM |
| Operating Income | $-110.66MM | $-21.90MM | $-84.77MM |
| Non-Operating Income | $13.33MM | $12.17MM | $9.89MM |
| R&D Expense | $71.80MM | $63.39MM | $56.10MM |
| Income(Loss) | $-97.33MM | $-9.72MM | $-74.88MM |
| Net Income(Loss)* | $-97.33MM | $-9.72MM | $-74.88MM |
| Stockholders Equity | $235.19MM | $243.03MM | $349.00MM |
| Assets | $257.69MM | $260.72MM | $366.28MM |
| Operating Cash Flow | $-90.97MM | $-2.22MM | $-60.06MM |
| Capital expenditure | $0.51MM | $0.28MM | $0.31MM |
| Investing Cash Flow | $-36.69MM | $32.23MM | $30.72MM |
| Financing Cash Flow | $118.12MM | $2.75MM | $168.67MM |
| Earnings Per Share** | $-1.59 | $-0.16 | $-1.18 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.